Back to Search
Start Over
Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
- Source :
-
Antiviral research [Antiviral Res] 2013 Aug; Vol. 99 (2), pp. 119-24. Date of Electronic Publication: 2013 May 14. - Publication Year :
- 2013
-
Abstract
- Monitoring hepatitis C virus (HCV) kinetics during antiviral treatment is recommended for determining the best form of treatment management. We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients. The viral kinetics of 65 patients with HCV genotype 1b was assessed. HCV RNA was tested at baseline, on day 3, and every week from 1 to 12 by both the first-generation Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV (CAP/CTM) assay and the Abbott RealTime HCV (ART) assay. A total of 910 serum samples were obtained from the 65 patients. Of these, 168 (28.5%) of the 590 samples HCV RNA negative by CAP/CTM were positive by ART. In contrast, 17 (3.9%) of the 439 samples HCV RNA negative by ART were positive by CAP/CTM. The rates of HCV RNA negativity by ART at weeks 3, 4, and 5 were significantly lower than those by CAP/CTM (21.5% vs. 50.8%, 36.9% vs. 70.8% and 44.6% vs. 81.5%; P<0.001, P<0.0001 and P<0.05, respectively). Although the ART is superior for the determination of HCV RNA negativity, the predictive value of detectable HCV RNA for non-sustained virological response (non-SVR) by CAP/CTM is higher than by ART at weeks 4, 6, and 8. We also found that 16 (24.6%) by CAP/CTM and 28 (43.1%) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period. However, the reappearance of residual HCV RNA was not associated with non-SVR. In conclusion, a significant difference was found between the two real-time PCR assays for the assessment of virological response based on undetectable HCV RNA.<br /> (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Subjects :
- Aged
Drug Therapy, Combination
Female
Humans
Interferon-alpha therapeutic use
Male
Middle Aged
Polyethylene Glycols therapeutic use
Polymerase Chain Reaction
Recombinant Proteins therapeutic use
Ribavirin therapeutic use
Antiviral Agents therapeutic use
Hepacivirus genetics
Hepatitis C, Chronic drug therapy
Oligopeptides therapeutic use
RNA, Viral blood
Subjects
Details
- Language :
- English
- ISSN :
- 1872-9096
- Volume :
- 99
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Antiviral research
- Publication Type :
- Academic Journal
- Accession number :
- 23684903
- Full Text :
- https://doi.org/10.1016/j.antiviral.2013.05.002